Ross Keller, PhD
@rossk11.bsky.social
Senior Research Director at Private Health Management. Previously, Research Fellow at MSKCC working on cancer genomics and PhD at Penn State University studying cancer evolution.
https://privatehealth.com/
https://privatehealth.com/
Reposted by Ross Keller, PhD
DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution www.nature.com/articles/s4...
September 27, 2025 at 2:15 PM
DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution www.nature.com/articles/s4...
Reposted by Ross Keller, PhD
FDA Approves Imlunestrant (Inluriyo) for ESR1-Mutated Metastatic Breast Cancer
oncodaily.com/fda-approval...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Imlunestrant #Inluriyo #mBC #BreastCancer
oncodaily.com/fda-approval...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Imlunestrant #Inluriyo #mBC #BreastCancer
FDA Approves Imlunestrant (Inluriyo) for ESR1-Mutated Metastatic Breast Cancer - OncoDaily
FDA Approves Imlunestrant (Inluriyo) for ESR1-Mutated Metastatic Breast Cancer / Breast Cancer, Cancer research, EMBER-3 trial, ESR1, ESR1 mutation,
oncodaily.com
September 27, 2025 at 2:25 PM
FDA Approves Imlunestrant (Inluriyo) for ESR1-Mutated Metastatic Breast Cancer
oncodaily.com/fda-approval...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Imlunestrant #Inluriyo #mBC #BreastCancer
oncodaily.com/fda-approval...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Imlunestrant #Inluriyo #mBC #BreastCancer
Reposted by Ross Keller, PhD
Among patients with locoregionally advanced nasopharyngeal carcinoma, toripalimab combination therapy without concurrent cisplatin was a feasible treatment with high efficacy in failure-free survival and low toxicity.
ja.ma/4mKcg5u
ja.ma/4mKcg5u
August 21, 2025 at 3:20 PM
Among patients with locoregionally advanced nasopharyngeal carcinoma, toripalimab combination therapy without concurrent cisplatin was a feasible treatment with high efficacy in failure-free survival and low toxicity.
ja.ma/4mKcg5u
ja.ma/4mKcg5u
Reposted by Ross Keller, PhD
Not just shingles vaccine, but also RSV vaccine reduces the risk of dementia, which highlights the benefit of revving up the immune system in older individuals
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections - npj Vaccines
npj Vaccines - Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections
www.nature.com
June 27, 2025 at 5:48 PM
Not just shingles vaccine, but also RSV vaccine reduces the risk of dementia, which highlights the benefit of revving up the immune system in older individuals
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Ross Keller, PhD
20 Posts Not to Miss from ASCO 2025
@ascocancer.bsky.social
@bookiephronesis.bsky.social
@ptarantinomd.bsky.social
@europeancancer.bsky.social
@drnataliagandur.bsky.social
oncodaily.com/societies/as...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO25
@ascocancer.bsky.social
@bookiephronesis.bsky.social
@ptarantinomd.bsky.social
@europeancancer.bsky.social
@drnataliagandur.bsky.social
oncodaily.com/societies/as...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO25
20 Posts Not to Miss from ASCO 2025 - OncoDaily
20 Posts Not to Miss from ASCO 2025 / American Society of Clinical Oncology, Armando Orlandi, ASCO, ASCO 2025, ASCO25, cancer, Chris Boshoff, Clifford Hudis,
oncodaily.com
June 7, 2025 at 8:58 PM
Reposted by Ross Keller, PhD
Rapid melanoma oral #7 ➡️ 5 year outcomes with lifileucel
-mDOR 36.5m
-31.3% of responders with sustained response
-3 pts with PR that deepened after about a year
-AEs within first 3 m and drop off dramatically
Theresa Medina U Colo
#ASCO25 @ascocancer.bsky.social
-mDOR 36.5m
-31.3% of responders with sustained response
-3 pts with PR that deepened after about a year
-AEs within first 3 m and drop off dramatically
Theresa Medina U Colo
#ASCO25 @ascocancer.bsky.social
June 2, 2025 at 4:03 PM
Rapid melanoma oral #7 ➡️ 5 year outcomes with lifileucel
-mDOR 36.5m
-31.3% of responders with sustained response
-3 pts with PR that deepened after about a year
-AEs within first 3 m and drop off dramatically
Theresa Medina U Colo
#ASCO25 @ascocancer.bsky.social
-mDOR 36.5m
-31.3% of responders with sustained response
-3 pts with PR that deepened after about a year
-AEs within first 3 m and drop off dramatically
Theresa Medina U Colo
#ASCO25 @ascocancer.bsky.social
Reposted by Ross Keller, PhD
LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC @danafarber.bsky.social @ascocancer.bsky.social #ASCO25 #lcsm #oncology www.onclive.com/view/lb2102-...
LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC
The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.
www.onclive.com
June 2, 2025 at 4:13 PM
LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC @danafarber.bsky.social @ascocancer.bsky.social #ASCO25 #lcsm #oncology www.onclive.com/view/lb2102-...
Reposted by Ross Keller, PhD
Dr. DeMichele highlights the importance of clinical utility.
- PFS2 did not reach the high bar for statistical significance. But should it have been defined with different parameters?
- No crossover is a limitation, and serial ctDNA is burdensome and costly.
#ASCO25
- PFS2 did not reach the high bar for statistical significance. But should it have been defined with different parameters?
- No crossover is a limitation, and serial ctDNA is burdensome and costly.
#ASCO25
June 1, 2025 at 8:06 PM
Dr. DeMichele highlights the importance of clinical utility.
- PFS2 did not reach the high bar for statistical significance. But should it have been defined with different parameters?
- No crossover is a limitation, and serial ctDNA is burdensome and costly.
#ASCO25
- PFS2 did not reach the high bar for statistical significance. But should it have been defined with different parameters?
- No crossover is a limitation, and serial ctDNA is burdensome and costly.
#ASCO25
Reposted by Ross Keller, PhD
Dr. Myriam Chalabi discusses ATOMIC, pointing out it's the most meaningful adjuvant data since the IDEA collaboration was presented at the ASCO Annual Meeting in 2017, and asks the right questions in this space: #ASCO25
June 1, 2025 at 6:20 PM
Dr. Myriam Chalabi discusses ATOMIC, pointing out it's the most meaningful adjuvant data since the IDEA collaboration was presented at the ASCO Annual Meeting in 2017, and asks the right questions in this space: #ASCO25
Reposted by Ross Keller, PhD
DFS improved with the addition of atezolizumab for mFOLFOX6 as adjuvant Rx for Stage III colon ca, HR = 0.50 (p<0.0001) meetings.asco.org/2025-asco-an...
June 1, 2025 at 6:14 PM
DFS improved with the addition of atezolizumab for mFOLFOX6 as adjuvant Rx for Stage III colon ca, HR = 0.50 (p<0.0001) meetings.asco.org/2025-asco-an...
Reposted by Ross Keller, PhD
What is the Breakthrough of BREAKWATER at #ASCO25?
www.nejm.org/doi/full/10....
The addition of targeted therapy toward BRAF V600E mutant colorectal cancers in first-line treatment led to a large improvement in survival (15 months!!) in a subtype of CRC which is historically deadly.
www.nejm.org/doi/full/10....
The addition of targeted therapy toward BRAF V600E mutant colorectal cancers in first-line treatment led to a large improvement in survival (15 months!!) in a subtype of CRC which is historically deadly.
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer | NEJM
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy
(oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic
colorectal cancer, an...
www.nejm.org
May 31, 2025 at 4:33 PM
What is the Breakthrough of BREAKWATER at #ASCO25?
www.nejm.org/doi/full/10....
The addition of targeted therapy toward BRAF V600E mutant colorectal cancers in first-line treatment led to a large improvement in survival (15 months!!) in a subtype of CRC which is historically deadly.
www.nejm.org/doi/full/10....
The addition of targeted therapy toward BRAF V600E mutant colorectal cancers in first-line treatment led to a large improvement in survival (15 months!!) in a subtype of CRC which is historically deadly.
Reposted by Ross Keller, PhD
new out in Nature today www.nature.com/articles/s41...
Cross-tissue multicellular coordination and its rewiring in cancer - Nature
Comprehensive single-cell transcriptomic analysis of 35 human tissues reveals 12 cross-tissue coordinated cellular modules that exhibit intramodule communication and dynamic changes with ageing, and w...
www.nature.com
May 28, 2025 at 4:10 PM
new out in Nature today www.nature.com/articles/s41...
Reposted by Ross Keller, PhD
Encouraging to see further improvements in multi-cancer early detection flood tests to pick up Stage 0/1 and this will undoubtedly continue
@naturemedicine.bsky.social
www.nature.com/articles/s41...
@naturemedicine.bsky.social
www.nature.com/articles/s41...
May 27, 2025 at 1:50 PM
Encouraging to see further improvements in multi-cancer early detection flood tests to pick up Stage 0/1 and this will undoubtedly continue
@naturemedicine.bsky.social
www.nature.com/articles/s41...
@naturemedicine.bsky.social
www.nature.com/articles/s41...
Reposted by Ross Keller, PhD
The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@elisaagostinetto.bsky.social
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@elisabettabonzano.bsky.social
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@elisaagostinetto.bsky.social
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@elisabettabonzano.bsky.social
May 23, 2025 at 10:05 AM
The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@elisaagostinetto.bsky.social
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@elisabettabonzano.bsky.social
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@elisaagostinetto.bsky.social
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@elisabettabonzano.bsky.social
Reposted by Ross Keller, PhD
Delighted to share that the results of my main postdoc project are now published in @nature.com
🔗 doi.org/10.1038/s415...
🔗 doi.org/10.1038/s415...
Multigenerational cell tracking of DNA replication and heritable DNA damage - Nature
A multigenerational single-cell tracking approach provides a framework to dissect phenotypic plasticity at the single-cell level, offering insights into cellular processes that may resemble early even...
doi.org
May 21, 2025 at 3:27 PM
Delighted to share that the results of my main postdoc project are now published in @nature.com
🔗 doi.org/10.1038/s415...
🔗 doi.org/10.1038/s415...
Reposted by Ross Keller, PhD
ASCO and Google Cloud to Deliver AI-Powered Tool that Provides Faster, Interactive Access to ASCO's Evidence-Based Clinical Guidelines www.asco.org/about-asco/p...
ASCO and Google Cloud to Deliver AI-Powered Tool that Provides Faster, Interactive Access to ASCO's Evidence-Based Clinical Guidelines - ASCO
www.asco.org
May 21, 2025 at 9:37 PM
ASCO and Google Cloud to Deliver AI-Powered Tool that Provides Faster, Interactive Access to ASCO's Evidence-Based Clinical Guidelines www.asco.org/about-asco/p...
Reposted by Ross Keller, PhD
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From CHRYSALIS
buff.ly/JIAtTJe
Findings support amivantamab as potential therapeutic option for METex14-altered NSCLC, even in those previously treated w/ MET inh
buff.ly/JIAtTJe
Findings support amivantamab as potential therapeutic option for METex14-altered NSCLC, even in those previously treated w/ MET inh
May 21, 2025 at 11:00 AM
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From CHRYSALIS
buff.ly/JIAtTJe
Findings support amivantamab as potential therapeutic option for METex14-altered NSCLC, even in those previously treated w/ MET inh
buff.ly/JIAtTJe
Findings support amivantamab as potential therapeutic option for METex14-altered NSCLC, even in those previously treated w/ MET inh
Reposted by Ross Keller, PhD
Our study on HPV45, a cancer-causing type of #HPV, is out in the International Journal of Cancer.
Compared to most other types, HPV45 disproportionately causes adenocarcinoma—a form of cervical cancer that often lacks easily detectable precursors. 1/5 onlinelibrary.wiley.com/doi/10.1002/...
Compared to most other types, HPV45 disproportionately causes adenocarcinoma—a form of cervical cancer that often lacks easily detectable precursors. 1/5 onlinelibrary.wiley.com/doi/10.1002/...
Whole‐genome sequencing of 1,083 HPV45 cases and controls identifies genetic variants associated with glandular cervical lesions
Little is known about how genetic variation in human papillomavirus type 45 (HPV45) influences its ability to cause cancer. Here, the authors conducted the largest whole-genome sequencing study to da...
onlinelibrary.wiley.com
May 19, 2025 at 4:29 PM
Our study on HPV45, a cancer-causing type of #HPV, is out in the International Journal of Cancer.
Compared to most other types, HPV45 disproportionately causes adenocarcinoma—a form of cervical cancer that often lacks easily detectable precursors. 1/5 onlinelibrary.wiley.com/doi/10.1002/...
Compared to most other types, HPV45 disproportionately causes adenocarcinoma—a form of cervical cancer that often lacks easily detectable precursors. 1/5 onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Ross Keller, PhD
💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure.
Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo
48% asian, 39% white.
9% discontinued due to side effects
@oncoalert.bsky.social
Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo
48% asian, 39% white.
9% discontinued due to side effects
@oncoalert.bsky.social
May 19, 2025 at 8:31 PM
💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure.
Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo
48% asian, 39% white.
9% discontinued due to side effects
@oncoalert.bsky.social
Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo
48% asian, 39% white.
9% discontinued due to side effects
@oncoalert.bsky.social
Reposted by Ross Keller, PhD
We’re thrilled that base editing, developed by researchers in the lab of Broad member David Liu, is having such a profound impact in the clinic. Congratulations to former Broad postdoc @kiranmusunuru.bsky.social & @childrensphila.bsky.social on their groundbreaking work. www.nejm.org/doi/full/10....
May 16, 2025 at 5:08 PM
We’re thrilled that base editing, developed by researchers in the lab of Broad member David Liu, is having such a profound impact in the clinic. Congratulations to former Broad postdoc @kiranmusunuru.bsky.social & @childrensphila.bsky.social on their groundbreaking work. www.nejm.org/doi/full/10....
Reposted by Ross Keller, PhD
So excited to share our latest work with @saratchandarlapaty.bsky.social, Antonio Marra, Andrea Gazzo @mskcancercenter.bsky.social out today in @natgenet.nature.com! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/
www.nature.com/articles/s41...
www.nature.com/articles/s41...
APOBEC3 mutagenesis drives therapy resistance in breast cancer - Nature Genetics
Analysis of a large cohort of metastatic breast cancer samples shows that APOBEC mutational signatures are enriched in post-treatment samples. APOBEC activity was also associated with mutations known ...
www.nature.com
May 16, 2025 at 12:01 PM
So excited to share our latest work with @saratchandarlapaty.bsky.social, Antonio Marra, Andrea Gazzo @mskcancercenter.bsky.social out today in @natgenet.nature.com! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Ross Keller, PhD
Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC)
www.jto.org/article/S155...
The review also examines the incidence of actionable mutations, toxicity considerations, sequencing strategies, and ongoing trials
www.jto.org/article/S155...
The review also examines the incidence of actionable mutations, toxicity considerations, sequencing strategies, and ongoing trials
May 14, 2025 at 12:50 PM
Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC)
www.jto.org/article/S155...
The review also examines the incidence of actionable mutations, toxicity considerations, sequencing strategies, and ongoing trials
www.jto.org/article/S155...
The review also examines the incidence of actionable mutations, toxicity considerations, sequencing strategies, and ongoing trials
Reposted by Ross Keller, PhD
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor
www.nature.com/articles/d41...
Verastem’s new therapy for a form of KRAS-mutated ovarian cancer combines the kinase inhibitors defactinib and avutometinib
www.nature.com/articles/d41...
Verastem’s new therapy for a form of KRAS-mutated ovarian cancer combines the kinase inhibitors defactinib and avutometinib
May 13, 2025 at 2:27 PM
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor
www.nature.com/articles/d41...
Verastem’s new therapy for a form of KRAS-mutated ovarian cancer combines the kinase inhibitors defactinib and avutometinib
www.nature.com/articles/d41...
Verastem’s new therapy for a form of KRAS-mutated ovarian cancer combines the kinase inhibitors defactinib and avutometinib
Reposted by Ross Keller, PhD
Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer.
We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting!
@oncbrothers.bsky.social
@oncoalert.bsky.social
www.astrazeneca.com/media-centre...
We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting!
@oncbrothers.bsky.social
@oncoalert.bsky.social
www.astrazeneca.com/media-centre...
Enhertu followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breas...
www.astrazeneca.com
May 7, 2025 at 1:01 PM
Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer.
We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting!
@oncbrothers.bsky.social
@oncoalert.bsky.social
www.astrazeneca.com/media-centre...
We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting!
@oncbrothers.bsky.social
@oncoalert.bsky.social
www.astrazeneca.com/media-centre...
Reposted by Ross Keller, PhD
Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 28th - May 4th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
May 5, 2025 at 1:28 PM
Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 28th - May 4th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch